Grifols SA (GRF):企業の財務・戦略的SWOT分析

◆英語タイトル:Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1678
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥14,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Grifols SA (GRF) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Grifols SA (Grifols) focuses on improving the health and well-being of people around the world. It conducts research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. The company has plasma donation centers across the US. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Barcelona, Spain.

Grifols SA Key Recent Developments

Mar 27,2020 Grifols and Shanghai RAAS close their strategic alliance in China
Mar 26,2020 Grifols teams up with US to test plasma therapy for Covid-19
Mar 25,2020 Grifols announces formal collaboration with US Government to produce the first treatment specifically targeting COVID-19
Feb 27,2020 Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Grifols SA – Key Facts
Grifols SA – Key Employees
Grifols SA – Key Employee Biographies
Grifols SA – Major Products and Services
Grifols SA – History
Grifols SA – Company Statement
Grifols SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Grifols SA – Business Description
Business Segment: Bio Supplies
Overview
Performance
Business Segment: Bioscience
Overview
Performance
Key Stats
Business Segment: Diagnostic
Overview
Performance
Key Stats
Business Segment: Hospital
Overview
Performance
Business Segment: Others
Overview
Performance
Geographical Segment: European Union
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: Spain
Performance
Geographical Segment: USA and Canada
Performance
R&D Overview
Grifols SA – SWOT Analysis
SWOT Analysis – Overview
Grifols SA – Strengths
Grifols SA – Weaknesses
Grifols SA – Opportunities
Grifols SA – Threats
Grifols SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grifols SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 27, 2020: Grifols and Shanghai RAAS close their strategic alliance in China
Mar 26, 2020: Grifols teams up with US to test plasma therapy for Covid-19
Mar 25, 2020: Grifols announces formal collaboration with US Government to produce the first treatment specifically targeting COVID-19
Feb 27, 2020: Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million
Feb 13, 2020: Grifols PharmacyKeeper ranked No. 1 in KLAS rating, extends category leadership
Dec 05, 2019: Grifols streamlines Hospital Pharmacy operations with new KIRO Fill technology and PharmacyKeeper enhancements
Jul 31, 2019: Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan
Jul 03, 2019: Grifols selected to build its first intravenous solutions manufacturing line in Africa
May 24, 2019: Grifols reinforces its long-term and sustainable growth strategy with EUR 1,400 million in capital investments in 2018-2022
May 08, 2019: Grifols reports 13% revenue growth to EUR 1,157 million and confirms its solid operational performance
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Grifols SA, Key Facts
Grifols SA, Key Employees
Grifols SA, Key Employee Biographies
Grifols SA, Major Products and Services
Grifols SA, History
Grifols SA, Other Locations
Grifols SA, Subsidiaries
Grifols SA, Key Competitors
Grifols SA, Ratios based on current share price
Grifols SA, Annual Ratios
Grifols SA, Annual Ratios (Cont...1)
Grifols SA, Annual Ratios (Cont...2)
Grifols SA, Interim Ratios
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grifols SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Grifols SA, Performance Chart (2015 - 2019)
Grifols SA, Ratio Charts
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Grifols SA (GRF):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • United Networks Ltd (UNL):企業の財務・戦略的SWOT分析
    United Networks Ltd (UNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析
    Summary Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company. The company is engaged in the development of therapeutic treatments for rare and orphan autoimmune and inflammatory diseases. It offers coversin drugs that act on complement component-C5 that hel …
  • Neurimmune Holding AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Neurimmune Holding AG (Neurimmune), formerly Neurimmune Therapeutics AG is a biopharmaceutical company that develops immunotherapeutics for human diseases. The company’s pipeline products include human-derived monoclonal antibodies developed for the treatment and prevention of human neurodeg …
  • Qatar Electricity & Water Co QPSC (QEWS):電力:M&Aディール及び事業提携情報
    Summary Qatar Electricity & Water Co QPSC (QEWC), formerly Qatar Electricity & Water Company QSC, is an electricity and water utility. It generates electricity and desalinates water. The company owns and operates various power generation and water desalination stations and substations primarily in Q …
  • Risk Strategies Company Inc:企業のM&A・事業提携・投資動向
    Risk Strategies Company Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Risk Strategies Company Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Tokyo Gas Co Ltd (9531):石油・ガス:M&Aディール及び事業提携情報
    Summary Tokyo Gas Co Ltd (Tokyo Gas) is a gas utility that produces, supplies and markets liquefied natural gas (LNG). It also produces, supplies and sells electricity. Tokyo Gas also has overseas upstream, midstream and downstream businesses. It provides engineering solutions, gas appliances and ga …
  • Bracco SpA:企業の戦略的SWOT分析
    Bracco SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • MOL Hungarian Oil and Gas PLC (MOL)-エネルギー分野:企業M&A・提携分析
    Summary MOL Hungarian Oil and Gas Public Limited Company (MOL) is an integrated oil and gas company. It explores develops and produces crude oil, natural gas. It conducts refining, transportation and storage of crude oil; wholesale and retail marketing of crude oil products, production and sale of p …
  • Zucara Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Zucara Therapeutics Inc (Zucara Therapeutics) is a pharmaceutical company that develops novel drug therapies to prevent hypoglycemia in people with diabetes. The company’s technology is used to prevent the dangerous low blood sugar by restoring the body’s ability to counter-regulate hypoglyc …
  • Continental AG (CON):企業の財務・戦略的SWOT分析
    Continental AG (CON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ARCA biopharma Inc (ABIO):医療機器:M&Aディール及び事業提携情報
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • RKW SE:企業の戦略的SWOT分析
    RKW SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Biogen Inc (BIIB):医療機器:M&Aディール及び事業提携情報
    Summary Biogen Inc (Biogen) is a global biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases worldwide. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fu …
  • Spectral Medical Inc (EDT):企業の財務・戦略的SWOT分析
    Summary Spectral Medical Inc (Spectral), formerly Spectral Diagnostics Inc, is a biotechnology company that develops and commercializes diagnostic solutions for patient management. The company’s products comprise EAA, PMX, SAMI, toraymyxin and reagents. Its EAA is an endotoxin activity assay, which …
  • Evergreen Packaging Inc:企業の戦略・SWOT・財務情報
    Evergreen Packaging Inc - Strategy, SWOT and Corporate Finance Report Summary Evergreen Packaging Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • NMDC Ltd:企業のM&A・事業提携・投資動向
    NMDC Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NMDC Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Harry Ramsden’s:企業の戦略・SWOT・財務分析
    Harry Ramsden's - Strategy, SWOT and Corporate Finance Report Summary Harry Ramsden's - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Fondation MEDINA-製薬・医療分野:企業M&A・提携分析
    Summary Fondation MEDINA (MEDINA) is a research organization that discovers biologically active molecules and drug candidates for unmet medical needs. The organization’s services include access to natural products libraries, drug discovery contract research with its high throughput screening platfor …
  • Carmell Therapeutics Corp:企業の製品パイプライン分析2018
    Summary Carmell Therapeutics Corp (Carmell) is a biotechnology company that develops and commercializes bone healing accelerants and tissue healing accelerants. Its pipeline portfolio include adjunctive treatment for long bone fractures in Phase I and Phase II a; and adjunctive treatment for total j …
  • CIRCOR Aerospace Products Group:企業の戦略・SWOT・財務情報
    CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report Summary CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆